LTR Pharma Secures Indian Patent for SPONTAN and ROXUS Technology
LTP: $0.455 +8.33% · MC: $86M
LTR Pharma has secured an Indian patent covering defined formulation characteristics of the nasal spray technology behind its SPONTAN and ROXUS erectile dysfunction treatments. Protection extends to May 2041, subject to maintenance requirements and continued validity. The company recently reported that the first ROXUS prescriptions had been fulfilled in the US and that more than 2,000 bottles of SPONTAN had been dispensed in Australia.

Comments